Oracle was at the center of all things artificial intelligence (AI) in 2025, and therefore at the center of the investing world. Here's why Oracle plays a linchpin role in the artificial intelligence ...

Oracle shares fell 45% from their peak despite finishing 2025 up 17%. Growing concern centers on Oracle’s debt levels and heavy reliance on OpenAI as a single client. It might be overdone in 2026.

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

Oracle's strong AI growth fuels investor interest in its booming cloud computing sector. Anyone can buy Oracle shares through a brokerage using specific order details. Oracle aims for double-digit ...

Hypertrophic cardiomyopathy (HCM) thickens the left ventricle in your heart, which can make pumping blood harder and raise the risk of complications if untreated. HCM symptoms can be mild or absent ...

S&P 500, Nasdaq close down as Big Tech's soaring AI budgets trigger flight The S&P 500 and the technology-heavy Nasdaq closed lower on Thursday as investors were rattled by the latest earnings reports ...

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It ...